Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Journal
Journal of clinical oncology
Journal Volume
40
Journal Issue
2
Pages
189-201
Date Issued
2022
Author(s)
Gibson C.J.
Kim H.T.
Zhao L.
Murdock H.M.
Hambley B.
Ogata A.
Madero-Marroquin R.
Wang S.
Green L.
Fleharty M.
Dougan T.
Blumenstiel B.
Cibulskis C.
Tsuji J.
Duran M.
Gocke C.D.
Antin J.H.
Nikiforow S.
DeZern A.E.
Chen Y.-B.
Ho V.T.
Jones R.J.
Lennon N.J.
Walt D.R.
Ritz J.
Soiffer R.J.
Gondek L.P.
Lindsley R.C.
Abstract
PURPOSE: Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain. PATIENTS AND METHODS: We performed targeted error-corrected sequencing on samples from 1,727 donors age 40 years or older and assessed the effect of donor CH on recipient clinical outcomes. We measured long-term engraftment of 102 donor clones and cytokine levels in 256 recipients at 3 and 12 months after transplant. RESULTS: mutations. CONCLUSION: -CH is associated with improved recipient survival because of reduced relapse risk and with an augmented network of inflammatory cytokines in recipients. Risk of DCL in allogeneic hematopoietic cell transplantation is driven by somatic myelodysplastic syndrome-associated mutations or germline predisposition in donors.
Type
journal article